/
Neurology
Ataxia
15
Pipeline Programs↗
32
Active Trials↗
31
Companies Involved↗
Ataxia is an emerging landscape with 15 programs across 31 companies. The most active players are Biogen, Design Therapeutics, Inc., Mario Negri Institute for Pharmacological Research. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 11
Phase 23
Phase 34
Approved
No programs
Analysis
Trial Status
112
clinical trials
Completed65 · 58%
Recruiting21 · 19%
Active, not recruiting6 · 5%
Not yet recruiting5 · 4%
Terminated5 · 4%
Unknown status5 · 4%
Other5 · 4%
Clinical Trials
Trial Activity
112 trials
Non-progressive Congenital Ataxia - Advancing Diagnosis to Enhance Chances for Targeted Therapy
Recruiting·—·N/A·NCT07421219·50 enrolled
Retraining Reaching in Cerebellar Ataxia
Recruiting·HHugo W. Moser Research Institute at Kennedy Krieger, Inc.·Preclinical·NCT03879018·18 enrolled
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)